8-K: RxSight Announces Preliminary Q1 2025 Revenue and Revises Full-Year Guidance

RxSight reports preliminary Q1 2025 revenue of approximately $37.9 million and adjusts its full-year 2025 revenue guidance downward due to headwinds in the premium IOL market.

Summary

• RxSight, Inc. announced preliminary revenue results for the first quarter of 2025 and revised full-year 2025 guidance.
• Preliminary first quarter 2025 revenue is expected to be approximately $37.9 million, a 28% increase compared to the prior year period but a 6% decrease compared to the fourth quarter of 2024.
• The company sold 27,579 Light Adjustable Lenses (LAL/LAL+), representing a 36% increase in procedure volume compared to Q1 2024.
• RxSight sold 73 Light Delivery Devices (LDDs), bringing the installed base to 1,044 LDDs as of March 31, 2025, a 43% expansion compared to the 732 LDDs at the end of Q1 2024.
• The company decreased its 2025 full-year revenue guidance to a range of $160.0 million to $175.0 million, down from the previous range of $185.0 million to $197.0 million.
• This revised revenue guidance represents implied growth of 14% to 25% compared to 2024.
• Operating expenses are now projected in the range of $150.0 million to $160.0 million, a decrease from the previous guidance range of $165.0 million to $170.0 million.
• Non-cash stock-based compensation expense is projected to be in the range of $27.0 million to $30.0 million, compared to the previous range of $22.0 million to $25.0 million.
• The company will host a conference call on April 3, 2025, to discuss these results and revised guidance.
• Unaudited financial results for the first quarter of 2025 are expected to be announced on Wednesday, May 7, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there's year-over-year revenue growth, the downward revision of full-year guidance and acknowledgement of market headwinds temper the positive aspects.

Positives

• Preliminary Q1 2025 revenue shows a 28% increase compared to the prior year period.
• The sale of Light Adjustable Lenses (LAL/LAL+) increased by 36% in procedure volume compared to Q1 2024.
• The installed base of Light Delivery Devices (LDDs) expanded by 43% compared to Q1 2024.
• Operating expense guidance for 2025 has been revised downward, indicating potential cost management.

Negatives

• Preliminary Q1 2025 revenue decreased by 6% compared to the fourth quarter of 2024.
• Full-year revenue guidance for 2025 has been revised downward, indicating potential challenges in achieving previous growth expectations.
• The company is facing headwinds affecting the overall premium IOL market and broader economy.
• Non-cash stock-based compensation expense is now projected to be higher than previously expected.

Risks

• The company faces headwinds affecting the overall premium IOL market and broader economy.
• The revised revenue guidance indicates potential challenges in achieving previous growth expectations.
• The preliminary financial results are subject to finalization and review by the company's independent registered public accounting firm.
• The company's actual results could differ based on completion of quarter-end closing procedures, final adjustments, and developments that may arise prior to completion of its quarterly financial statements.

Future Outlook

The company expects revenue in the range of $160.0 million to $175.0 million for 2025 and operating expenses in the range of $150.0 million to $160.0 million. They plan to refine clinical education and practice adoption programs, support new customer business models, drive innovative product enhancements, and advance international expansion.

Management Comments

• Dr. Ron Kurtz, Chief Executive Officer and President of RxSight, stated that the company must navigate headwinds affecting the overall premium IOL market and broader economy.
• Dr. Kurtz also mentioned that the company will continue to refine its clinical education and practice adoption programs, support new customer business models, drive innovative product enhancements, and advance international expansion.

Industry Context

The announcement highlights the challenges faced by RxSight due to headwinds in the premium IOL market, suggesting a broader slowdown or increased competition in the sector. The company's response includes refining its strategies and focusing on international expansion, which aligns with common industry practices to mitigate market-specific risks.

Comparison to Industry Standards

• Companies like Alcon, Johnson & Johnson Vision, and Bausch + Lomb are major players in the IOL market.
• RxSight's growth in LDD installed base to 1,044 units indicates a growing adoption of their technology, but the revised revenue guidance suggests they are facing challenges in converting this installed base into revenue.
• Compared to larger, more diversified companies, RxSight's performance is more sensitive to fluctuations in the premium IOL market.

Stakeholder Impact

• Shareholders may react negatively to the downward revision of revenue guidance.
• Employees may experience uncertainty due to the company's efforts to address market conditions.
• Customers (surgeons and practices) may be affected by changes in clinical education and practice adoption programs.
• Suppliers may be impacted by potential adjustments in the company's spending and production plans.

Next Steps

• The company will host a conference call on April 3, 2025, to discuss the preliminary results and revised guidance.
• The company plans to report unaudited financial results for the first quarter of 2025 after the market close on Wednesday, May 7, 2025.

Key Dates

Keywords

RxSight, revenue, guidance, Light Adjustable Lens, Light Delivery Device, ophthalmic, cataract surgery, financial results